0%
0%
0%
0%
0%
About Vir Biotechnology, Inc
Sector
Health Technology
Industry
Biotechnology
CEO
Marianne de Backer
Website
vir.bio
Headquarters
San Francisco
Employees
576
Founded
2016
ISIN
US92764N1028
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
WATCH $VIRBullish
Fundamental
- High inflationary Macro environment / no fear sentiment
- Funds Accumulation
- Positive PE
- Positive PEG
- Positive P/FCF
- Top Sector / Industry
- Moderate floats
- High short interest / 7 days + 58%
- Impressive sales ?
Technical
- - Momentum Theory Indicator - N
VIR : hold on and be patient After the very good results of the first quarter,the stock reacted well. The hepatitis cases remain under control. The company's balance sheet is clean and this gives hope for the future...
VIR - the fundamental playThere is something that market is wrong about. The VIR and its blockbuster drug. This drug earns $1-1.5B per Q.
+ they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES!
And market prices them like @#$! while they will earn around their own 1x marke
VIR Double Falling WedgeAnalysis for VIR
Two falling wedges can be seen to have formed in this current down move
As in the previous down move, price temporarily moves out of the channel before moving back up
This is what's occurring now with this second falling wedge
I do expect a big break out at this huge support area
$VIR entry PT 42-44 Long term Target PT 200HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
KEY POINTS:
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmit
VIR - BREAKOUT IN THE HORIZON - POSSIBLY IN JAN/FEB 2022The VIR weekly chart shows an obvious resemblance between Phase 1 and Phase 2, so we can expect a breakout to $80-90 zone on good news, for example Q4 Earning report with Covid treatmengt Sotrovimab sales worldwide or good trial readouts from their developing products, when the Phase 2 completed.
N
See all ideas
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
